Article Text

Download PDFPDF
4CPS-086 Proposal to darunavir (drv) the least trough plasma level (tpl) cut-off to estimate plasma hiv viral load (hvl) equal or less than 20 copies/ml
  1. FJ Parada Saavedra1,
  2. FI Torres Bondia1,
  3. A Aragonés Eroles2,
  4. SM Cano Marrón1,
  5. L Vállez Valero1,
  6. M Gilabert Sotoca1,
  7. JA Schoenenberger Arnaiz1
  1. 1Hospital Arnau de Vilanova de Lleida, Pharmacy, Lleida, Spain
  2. 2IRB Lleida, Pharmacoepidemiology, Lleida, Spain


Background Darunavir (DRV) is a high genetic barrier protease inhibitor, which when it is combined with a booster drug such as ritonavir or cobicistat, has shown high effectiveness in wild types such as resistant strains of HIV. The lack of conclusive population studies has determined a consensual cut-off level using the IC50, which in its wild type is 55 mcg/l and in resistant strains is 550 mcg/l.

Purpose To find our TPL of DRV from which below this cut-off we can estimate HVL >20 copies/ml.

Material and methods Our prospective observational study included 51 HIV patients in treatment with the HAART scheme tenofovir disoproxil fumarate +emtricitabine + DRV 800 mg once a day (QD) for at least 4 months, registered previously with some drug-related problem (DRP) (non-compliance suspicion, drug adverse events and persistent or first positive viral loads during HAART scheme). One hundred and twenty TPL were collected and determined by high performance liquid chromatography (HPLC) and with the same samples also were also determined HVL by real-time polymerase chain reaction assay (rtPCR). Patients who needed more than one sample period between sampling were 1 month. We divided all the TPL in two groups, where 1000 mcg/l was a random cut-off. In each group, we established the proportion of patients with HVL >20 copies/ml.

Results Twenty-six samples were included in group 1 (TPL <1000 mcg/L) and 94 in group 2 (TPL >1000 ng/ml). Samples related to HVL >20 copies/ml were 23 from group 1 (88.5%) and 58 from group 2 (61.7%). The proportional difference between this high HVL in both groups were statistically significant (Chi-square test p<0. 05). The relative risk to have HVL >20 copies/ml was 1.43 (95% CI: 1.16 to 1.77) in favour of group 1.

Conclusion Patients with TPL <1000 mcg/L could have a major risk of therapeutic failure measured by HVL >20 copies/ml. We need to increase the size of population in this study to confirm this cut-off.

No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.